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Abstract
Introduction No evidence based treatment is available for
atelectasis. We aimed to evaluate the clinical and radiologic
changes in pediatric patients who received DNase for persistent
atelectasis that could not be attributed to cardiovascular
causes, and who were unresponsive to treatment with inhaled
bronchodilators and physiotherapy.
Methods All non-cystic fibrosis pediatric patients who received
nebulised or endotracheally instilled DNase for atelectasis
between 1998 and 2002, with and without mechanical
ventilation, were analysed in a retrospective descriptive study.
The endpoints were the blood pCO2, the heart rate, the
respiratory rate, the FiO2 and the chest X-ray scores before and
after treatment.
Results In 25 of 30 patients (median [range] age, 1.6 [0.1–11]
years) who met inclusion criteria, paired data of at least three
endpoints were available. All clinical parameters improved
significantly within 2 hours (P < 0.01), except for the heart rate
(P = 0.06). Chest X-ray scores improved significantly within 24
hours after DNase treatment (P  < 0.001). Individual
improvement was observed in 17 patients and no clinical
change was observed in five patients. Temporary deterioration
(n = 3) was associated with increased airway obstruction and
desaturations. No other complications were observed.
Conclusion After treatment with DNase for atelectasis of
presumably infectious origin in non-cystic fibrosis pediatric
patients, rapid clinical improvement was observed within 2
hours and radiologic improvement was documented within 24
hours in the large majority of children, and increased airway
obstruction and ventilation–perfusion mismatch occurred in
three children, possibly due to rapid mobilisation of mucus.
DNase may be an effective treatment for infectious atelectasis in
non-cystic fibrosis pediatric patients.
Introduction
Atelectasis is a problem in many children with respiratory
infections or who require ventilation. At least 8% of children on
mechanical ventilation develop pulmonary atelectasis, with a
concomitant increase in the morbidity and the length of stay
[1]. There is no 'golden standard' for treatment of atelectasis
in children. Efficacy of treatment modalities such as inhaled
bronchodilators, steroids, physiotherapy and nebulised
sodium chloride (NaCl 0.9%) has not been demonstrated [2].
Atelectasis is commonly caused by sputum blocking the air-
w a y s .  M u c u s  i n  p a t i e n t s  w i t h  c y s t i c  f i b r o s i s  ( C F )  [ 3 ] ,  i n
patients with bronchiectasis [4] and in patients with respira-
tory syncytial virus (RSV) bronchiolitis [5] contains significant
amounts of extracellular DNA from degenerating leucocytes
and epithelial debris. DNA increases the viscosity and adhe-
siveness of lung secretions [6]. Recombinant human DNase
(rhDNase) has proven to be an effective treatment in opening
airways in CF [7-9]. In infections complicated by atelectasis,
bronchial secretions and mucus plugs also have a high
CF = cystic fibrosis; CXR = chest X-ray; FiO2 = Fraction of inspired Oxygen ; HR = heart rate; pCO2 = Pressure of CO2; rhDNase = recombinant 
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concentration of DNA [5], such that DNase could also be an
effective treatment in this situation.
Until now only case reports on the efficacy of DNase treatment
in atelectasis have been published, suggesting efficacy [5,10-
14] No randomised study has been published. The present
study analysed the resolution of atelectasis following treat-
ment with DNase in a large series of hospitalised children who
were refractory to conventional treatment.
Materials and methods
Study subjects
This retrospective study included all patients who received
rhDNase as treatment for atelectasis in patients with sus-
pected or proven lower airway infection at Sophia Children's
hospital, Rotterdam between 1998 and 2002. Patients were
identified through the computerised pharmacy registration.
Patients were included in the analysis when they had pulmo-
nary atelectasis of at least one lobe, and when rhDNase was
administered for that reason. CF patients were excluded and
all other patients were evaluated. Thirty patients and 32 epi-
sodes of atelectasis were identified, and this included patients
described previously [14]. When more than one atelectasis
was treated, only the first episode was included in the analysis.
Table 1 presents the demographic data of the study group.
The median age of the study group was 1.6 years. Sixteen
patients were younger than 1 year of age; two of these
patients were born prematurely at 26 weeks gestation, but
were 6 months and 7 months corrected postnatal age at the
time of admission. Sixteen patients were intubated in the days
before receiving rhDNase (median, 3 days; range, 1–16 days).
Twenty-five patients were treated in a pediatric intensive care
unit, and five patients were treated in a medium care unit.
Underlying illnesses or predisposing factors for severe lower
airways infections were: airway malacia (seven patients),
severe psychomotor retardation (five patients), congenital
heart disease (five patients: three children with ventricular sep-
tal defect, one child with tetralogy of fallot, and one child with
hypoplastic right ventricle, pulmonary atresia and blalock taus-
sig shunt), tracheostomy (four patients), bronchopulmonary
dysplasia (three patients), epilepsy (three patients), neuromus-
cular disease (two patients) and bronchiectasis (one patient).
Because rhDNase was administered as a part of patient care
and not as a medical trial, formal approval from an institutional
review board or a medical ethics committee was not required
in our hospital, and was therefore not requested.
Methods
RhDNase was only considered and administered when
patients did not demonstrate clinical improvement following
empirical treatment for atelectasis and still demonstrated sig-
nificant elevated work of breathing, could not be weaned eas-
ily off the ventilator or improved too slowly or not at all.
RhDNase (Pulmozyme®; Roche, Basel, Switzerland) was
administered either as a 2.5 mg dose nebulised twice daily
with a jet nebuliser, using a tight-fitting mask and high-flow
oxygen, in children breathing spontaneously, or 10% of this
dose was diluted to 5 ml with NaCl 0.9% and given slowly as
droplets during 30 min into the endotracheal tube or the can-
ula twice daily. This treatment was continued until the atelecta-
sis had improved sufficiently, preferably based on the chest X-
ray (CXR) of the next day. This dose was chosen as it was esti-
mated that pulmonary deposition of a regular 2.5 mg dosage
would be a maximal 10%. When rhDNase was instilled
endotracheally, it was attempted to position the head as favo-
rably as possible for the DNase to reach the affected lobe(s).
RhDNase was administered twice daily until patients improved
clinically because it was assumed that deposition in the
peripheral airways of these children would be significantly
diminished due to airway obstruction. All ventilated patients
were sedated according to protocol, but were not paralysed,
and the ventilators were standard not in the controlled ventila-
tory mode but in the pressure-regulated volume control mode.
Blood gas control values were only obtained when the
patients were stable, at least 30 min after manipulation or
endotracheal suctioning.
Following rhDNase administration, the ventilator settings were
not altered until the results of the blood gas analyses were
available (2 hours later), except in the case of clinical deterio-
ration. The nursing staff was only instructed to taper off FiO2
as much as possible. The clinical parameters analysed were
the heart rate (HR), the respiratory rate (RR), the capillary or
arterial pCO2, and the FiO2 before and within 2 hours follow-
ing administration of rhDNase. Evidence for atelectasis on
CXR was quantified using a CXR score before and within 24
hours of treatment with rhDNase. In children on mechanical
ventilation, the peak inspiratory pressure, the mean airway
pressure, days on the ventilator before receiving rhDNase and
the time to extubation were recorded. All parameters and side
effects were collected from patient files. In pediatric intensive
care patients, dates were also obtained from the computer-
ised data management system.
As cardiorespiratory endpoints we considered the change in
clinical parameters (RR, HR, FiO2, PCO2) before and within 2
hours after the first dose of rhDNase, and considered the CXR
score before and within 24 hours after the first dose of rhD-
Nase. Parameters were compared using the Wilcoxon signed
rank test. Interobserver comparisons of CXR scores were
made using Cohen's kappa. Overall individual improvement in
patients was defined as the improvement of two or more
endpoints.
Analysis
Clinical parameters
Parameters were compared before and within 2 hours after
treatment with rhDNase.Available online http://ccforum.com/content/9/4/R351
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Individual improvement of the FiO2, the RR and the HR was
defined as >10% decrease, and deterioration was defined as
>10% increase. Individual improvement of pCO2 was defined
as a decrease >1 kPa, and deterioration was defined as an
increase >1 kPa. When patients were on mechanical ventila-
tion, the peak inspiratory pressure and the mean airway pres-
sure improvement was defined as >3 cmH2O decrease of
pressure and their deterioration was defined as >3 cmH2O
increase of pressure.
Radiology
Anteroposterior CXRs before and within 24 hours after treat-
ment with rhDNase were coded, blinded and interpreted ran-
domly by two independent pediatric radiologists. Since a
validated scoring system for atelectasis is lacking, a scoring
system based on available literature [15-17] and personal
experience of our radiologists was defined as follows.
Each X-ray was scored for atelectasis, hyperinflation and
mediastinal shift. The presence or absence of hyperinflation
was marked as 1 point or 0 points, respectively. The presence
or absence of a mediastinal shift was scored as 1 or 0. Atel-
ectasis was scored for each lobe. A partial atelectasis of one
pulmonary lobe was scored as 1 point, and complete atelecta-
sis of one lobe was marked as 2 points. The distinction
between infiltrate and atelectasis was left up to the pediatric
radiologist, and was judged similarly to that in routine clinical
care. These results were summed for each CXR. The CXR
score before rhDNase treatment was compared with the CXR
score within 24 hours after treatment.
Results
Treatment
Conventional treatment of atelectasis before the use of rhD-
Nase consisted of nebulised bronchodilators in 25 patients,
nebulised NaCl 0.9% in 16 patients, systemic or inhaled glu-
cocorticoids in 18 patients and physiotherapy in all patients.
RhDNase was nebulised in 18 patients and was given as a
droplet in 12 patients on mechanical ventilation. All patients
received antibiotics after obtaining the appropriate cultures
because bacterial infections could not be ruled out and these
children had elevated inflammatory markers and were seri-
ously ill.
RhDNase administration
In 25 out of 30 patients who met the inclusion criteria, paired
data of at least three cardiorespiratory endpoints were availa-
ble. Individual values before and after rhDNase treatment are
shown in Fig. 1. Group results are presented in Table 2. All
clinical variables, except the HR, show a significant improve-
ment within 2 hours following rhDNase treatment (P < 0.01,
Fig. 1).
Anteroposterior CXRs before and within 24 hours after treat-
ment were obtained in 22 of 30 patients. On average, the
median CXR score improved from 4.0 to 2.0 (P < 0.001). No
paired CXRs were available in eight patients. In seven of these
eight patients, the hospital records documented that no CXR
was made after rhDNase treatment because the clinical
improvement was very obvious and another CXR was unnec-
essary. One patient died before a post-treatment CXR was
made when all treatment, including mechanical ventilation,
was discontinued because of the very poor prognosis of her
mitochondrial encephalomyopathy. Three patients showed
complete resolution of all atelectasis within 24 hours. Individ-
ual CXR improvement was observed in 17 patients, no clear
change was seen in two patients and deterioration was
observed in three patients. Agreement between the CXR
scores by the two observers expressed as Cohen's kappa was
0.61 (P < 0.001).
Individual improvement of at least two endpoints was seen in
17 patients, but no clinical change was observed in five
patients. Three patients on mechanical ventilation (two ex-pre-
mature infants now 6 months and 7 months corrected post-
gestational age with RSV bronchiolitis, and one 6-month-old
full-term child with congenital airway narrowing with an aden-
ovirus respiratory infection) showed an immediate deteriora-
tion after administration of rhDNase. This was possibly due to
excessive mobilisation of mucus leading to temporary
increased airway obstruction. Oxygenation was extremely dif-
ficult for 2 hours after administration of rhDNase in two of
these patients. Oxygen saturations remained between 85%
and 90%, despite increased ventilator settings. No other side
effects were observed.
Twelve of the 16 patients on mechanical ventilation were extu-
bated within 6 days after the onset of rhDNase treatment; six
Table 1
Demographic data of the study group
Sex (male/female) 19/11
Median (range) age 1.6 years (14 days–12 years)
Median (range) duration of disease before atelectasis 12 days (2–365 days)
On ventilator/no ventilator 16/14
Intensive care/medium care 25/5Critical Care    Vol 9 No 4    Hendriks et al.
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of these were extubated the day after administration of rhD-
Nase. Four patients remained on mechanical ventilation for
longer than 10 days.
Discussion
This retrospective series, being the largest study so far, sug-
gests that rhDNase may be an effective drug in the treatment
of refractory atelectasis in non-CF patients. Quick resolution of
atelectasis is important to reduce the number of days on
mechanical ventilation with associated morbidity and to pre-
vent the need for therapeutic bronchoscopy. Several case
reports [10-14] and one randomised study on RSV bronchioli-
tis [5] suggest a clinical and radiological improvement after
treatment with rhDNase in patients with atelectasis. In the
present study rhDNase was administered when an infection
was proven or suspected, and when patients had severe res-
piratory problems due to atelectasis.
Individual improvement of at least two endpoints was
observed in 17 patients, and mobilisation of sputum occurred
so rapidly in three children that this resulted in temporary wors-
ening of the ventilation perfusion mismatch due to increased
airway obstruction. Clinical improvement was observed in
most of the children within 2 hours, and the mean values of the
RR, pCO2 and FiO2 all improved significantly after rhDNase
treatment. One could argue that the improvement of these res-
Figure 1
Change of cardiorespiratory parameters before and after treatment Change of cardiorespiratory parameters before and after treatment. Individual changes of the heart rate, breathing frequency, blood pCO2 and FiO2 
before and within 2 hours, and the chest X-ray score before and within 24 hours after administration of DNase in 30 children treated for atelectasis. 
Although changes were statistically significant, a significant overlap was present before and after recombinant human DNase treatment (see also 
Table 1).
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piratory parameters is statistically significant, but is not clini-
cally relevant. However, the extubation rate and CXRs do
suggest a clinically relevant effect. A substantial number of
ventilated patients (six out of 16) with refractory atelectasis
could be extubated within 24 hours following the first dose of
rhDNase, and CXRs improved in 17 out of 22 cases within 24
hours. As in the study by Nasr and colleagues [5], CXRs were
scored by two independent radiologists, thereby preventing
observer bias. Agreement between the two pediatric radiolo-
gists can be considered satisfactory. Furthermore, the
degrees of improvement of CXRs scored by each radiologist
were also similar. Nasr and colleagues studied CXRs in infants
with RSV bronchiolitis before and after treatment with rhD-
Nase [5]. It is difficult to compare their results with those of the
present study as they interpreted the change in CXR on
admission and at discharge, they administered rhDNase only
once daily and they used a different CXR score, reflecting
CXR features of bronchiolitis. They found a small but signifi-
cant improvement of the CXR score after rhDNase, while their
control group showed a significant deterioration.
The deterioration with increased airway obstruction and venti-
lation-perfusion mismatch in three children on mechanical ven-
tilation was interpreted as a result of rapid mobilisation of
mucus in these three patients. This deterioration was
observed in three out of 12 infants, but not in the seven chil-
dren who were younger than these three patients. In a suba-
nalysis no relationship was found between this deterioration
and viral infection. We speculate that this deterioration may be
due to the mode of administration. If the drug is instilled, the
effective lung dose may be far greater than when it is inhaled;
in all three patients, rhDNase was instilled endotracheally.
Instillation may be an attractive option in that nebulised rhD-
Nase administration in patients on mechanical ventilation
results in significant deposition of the drug in the ventilator tub-
ing, but it may also imply a risk. To prevent deterioration follow-
ing instillation, however, lower starting doses of instilled
rhDNase may be warranted. The dose we used for instillation
was higher than reported by Boeuf and colleagues [11] and
was lower than that administered bronchoscopically by Dur-
ward and colleagues [12]. Incidentally, in the case reports
mentioned earlier, no clinical deterioration was observed when
rhDNase was nebulised or was instilled bronchoscopically. In
the randomised clinical trial on RSV bronchiolitis [5], a benefi-
cial effect and no adverse events were observed. This was
possibly also explained by using nebulised rhDNase rather
than instilled rhDNase. In the present study, none of the known
adverse effects such as pharyngitis, airway irritation, laryngitis,
conjunctivitis or rash were observed, nor any rebound effects
within 24 hours following administration.
There are several limitations to this study. First, it is a retro-
spective and open study potentially suffering from selection
effects, and lacking a control group. Second, there are no val-
idated scoring systems for atelectasis on CXR. Third, the spu-
tum DNA content was not known, and rhDNase was
administered irrespectively. Hence, the present study does not
provide ultimate proof that improvement should be attributed
to rhDNase treatment.
However, an association between drug treatment and a bene-
ficial clinical response is more likely to be causal when the
response follows immediately or quickly after administration of
the drug, when the response is consistent, when the response
is marked and when the response is plausible with respect to
the pathophysiology behind the disorder. In addition, the quick
alterations following rhDNase administration are also consist-
ent with in vitro experiments that demonstrated a quick effect
on sputum characteristics [1,18]. We therefore think that there
is a causal relationship between DNase administration and the
clinical outcome, but further randomised control trials are
required to confirm this.
In addition, because rhDNase is expensive, a cost-benefit cal-
culation in such a trial is warranted. Effective treatment of atel-
ectasis is likely to reduce the stay in the hospital. Daily
treatment costs of €60 should ideally reduce the length of
hospital stay and outweigh the costs of hospital stay (which
would be €1000/day in The Netherlands).
Conclusion
We conclude that our observations suggest efficacy of the
drug in at least 17/25 (68%) of the patients, and show com-
plete resolution of all atelectasis in three patients within 1 day.
Table 2
Clinical variables before and after administration of recombinant human DNase
Variable Before After P
Heart rate (beats/min) 150 (121–164) 130 (115–145) 0.06
Respiratory rate 41 (26–60) 36 (25–40) 0.01
PCO2 (kPa) 6.55 (5.7–8.6) 6.00 (5.3–7.5) 0.005
FiO2 (%) 50 (40–100) 40 (21–75) <0.001
Chest X-ray score 4 (2–6) 2 (0–4) <0.001
Data presented as the median (interquartile range). Comparisons were made using the Wilcoxon signed rank test.Critical Care    Vol 9 No 4    Hendriks et al.
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RhDNase may hence have a place in the treatment of children
with atelectasis. However, randomised controlled studies are
needed to prove this, and also to assess whether it is cost-
beneficial and can shorten the hospital stay of children with
atelectasis.
Competing interests
The author(s) declare that they have no competing interests.
Authors' contributions
TH performed data analysis and contributed to the manuscript.
MdH provided clinical care and contributed to the manuscript.
MHL performed radiology data analyses and designed the
study. ASD performed radiology data analyses and designed
the study. PJFM performed data analysis and contributed to
the manuscript.
References
1. Rivera R, Tibballs J: Complications of endotracheal intubation
and mechanical ventilation in infants and children. Crit Care
Med 1992, 20:193-199.
2. Peroni DG, Boner AL: Atelectasis: mechanisms, diagnosis and
management. Paediatr Respir Rev 2000, 1:274-278.
3. Shak S, Capon DJ, Hellmiss R, Marsters SA, Baker CL: Recom-
binant human DNase I reduces the viscosity of cystic fibrosis
sputum. Proc Natl Acad Sci USA 1990, 87:9188-9192.
4. Picot R, Das I, Reid L: Pus, deoxyribonucleic acid, and sputum
viscosity. Thorax 1978, 33:235-242.
5. Nasr SZ, Strouse PJ, Soskolne E, Maxvold NJ, Garver KA, Rubin
BK, Moler FW: Efficacy of recombinant human deoxyribonucle-
ase I in the hospital management of respiratory syncytial virus
bronchiolitis. Chest 2001, 120:203-208.
6. Puchelle E, Zahm JM, de Bentzmann S, Grosskopf C, Shak S,
Mougel D, Polu JM: Effects of rhDNase on purulent airway
secretions in chronic bronchitis. Eur Respir J 1996, 9:765-769.
7. Fuchs HJ, Borowitz DS, Christiansen DH, Morris EM, Nash ML,
Ramsey BW, Rosenstein BJ, Smith AL, Wohl ME: Effect of aero-
solized recombinant human DNase on exacerbations of respi-
ratory symptoms and on pulmonary function in patients with
cystic fibrosis. The Pulmozyme Study Group. N Engl J Med
1994, 331:637-642.
8. Harms HK, Matouk E, Tournier G, von der Hardt H, Weller PH,
Romano L, Heijerman HG, FitzGerald MX, Richard D, Strandvik B,
et al.:  Multicenter, open-label study of recombinant human
DNase in cystic fibrosis patients with moderate lung disease.
DNase International Study Group.  Pediatr Pulmonol 1998,
26:155-161.
9. Quan JM, Tiddens HA, Sy JP, McKenzie SG, Montgomery MD,
Robinson PJ, Wohl ME, Konstan MW, Pulmozyme Early Interven-
tion Trial Study Group: A two-year randomized, placebo-con-
trolled trial of dornase alfa in young patients with cystic
fibrosis with mild lung function abnormalities. J Pediatr 2001,
139:813-820.
10. Voelker KG, Chetty KG, Mahutte CK: Resolution of recurrent
atelectasis in spinal cord injury patients with administration of
recombinant human DNase.  Intensive Care Med 1996,
22:582-584.
11. Boeuf B, Prouix F, Morneau S, Marton D, Lacroix J: Safety of
endotracheal rh DNase (Pulmozyme) for treatment of pulmo-
nary atelectasis in mechanically ventilated children.  Pediatr
Pulmonol 1998, 26:147.
12. Durward A, Forte V, Shemie SD: Resolution of mucus plugging
and atelectasis after intratracheal rhDNase therapy in a
mechanically ventilated child with refractory status
asthmaticus. Crit Care Med 2000, 28:560-562.
13. El Hassan NO, Chess PR, Huysman MW, Merkus PJ, de Jongste
JC: Rescue use of DNase in critical lung atelectasis and mucus
retention in premature neonates.  Pediatrics 2001,
108:468-470.
14. Merkus PJ, de Hoog M, van Gent R, de Jongste JC: DNase treat-
ment for atelectasis in infants with severe respiratory syncytial
virus bronchiolitis. Eur Respir J 2001, 18:734-737.
15. Friis B, Eiken M, Hornsleth A, Jensen A: Chest X-ray appearances
in pneumonia and bronchiolitis. Correlation to virological diag-
nosis and secretory bacterial findings.  Acta Paediatr Scand
1990, 79:219-225.
16. Babcook CJ, Norman GR, Coblentz CL: Effect of clinical history
on the interpretation of chest radiographs in childhood
bronchiolitis. Invest Radiol 1993, 28:214-217.
17. Nasr SZ, Kuhns LR, Brown RW, Hurwitz ME, Sanders GM,
Strouse PJ: Use of computerized tomography and chest x-rays
in evaluating efficacy of aerosolized recombinant human
DNase in cystic fibrosis patients younger than age 5 years: a
preliminary study. Pediatr Pulmonol 2001, 31:377-382.
18. Dawson M, Wirtz D, Hanes J: Enhanced viscoelasticity of human
cystic fibrotic sputum correlates with increasing microhetero-
geneity in particle transport.  J Biol Chem 2003,
50:50393-50401.
Key messages
•  Rapid clinical and radiological improvement was 
observed in the large majority of children following rhD-
Nase treatment for atelectasis.
•  Increased airway obstruction and ventilation-perfusion 
mismatch may occur when rhDNase is instilled endotra-
cheally, possibly due to rapid mobilisation of mucus.
•  DNase may be an effective and cost-beneficial treat-
ment for atelectasis in non-CF pediatric patients.